Weak Trigger
now
Prevails in critical US patent interference litigation regarding foundational CRISPR-Cas12a gene-editing intellectual property, securing technical exclusivity.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |